Evidence map›Paper›PMID 38441954›Full record

ArticleJournal of medical Internet research2024

The Digital Therapeutics Real-World Evidence Framework: An Approach for Guiding Evidence-Based Digital Therapeutics Design, Development, Testing, and Monitoring.

Meelim Kim, Kevin Patrick, Camille Nebeker, Job Godino, Spencer Stein, Predrag Klasnja, Olga Perski, Clare Viglione, Aaron Coleman, Eric Hekler

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Mobile Health Interventions for Substance Use Disorders.Annual review of clinical psychology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meelim KimHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0002-0507-1727
Kevin PatrickHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0002-7334-3042
Camille NebekerHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0001-6819-1796
Job GodinoHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0002-4852-6277
Spencer SteinSpiral Health Inc, San Diego, CA, United States.ORCID 0009-0005-9419-679X
Predrag KlasnjaSchool of Information, University of Michigan, Ann Arbor, MI, United States.ORCID 0000-0002-4570-703X
Olga PerskiHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0003-3285-3174
Clare ViglioneHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0003-0958-8229
Aaron ColemanSmall Steps Labs LLC dba Fitabase Inc, San Diego, CA, United States.ORCID 0009-0001-2192-5809
Eric HeklerHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, United States.ORCID 0000-0002-7434-0775

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Optimizing Individualized and Adaptive mHealth Interventions via Control Systems Engineering MethodsR01CA244777 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HEKLER, ERIC, RIVERA, DANIEL E · 2020 to 2024
$3.8M
Operationalizing Behavioral Theory for mHealth: Dynamics, Context, and PersonalizationU01CA229445 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KLASNJA, PREDRAG, MARLIN, BENJAMIN M. · 2018 to 2022
$2.1M
SCH: Control Systems Engineering for Counteracting Notification Fatigue: An Examination of Health Behavior Change R01LM013107 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HEKLER, ERIC, KLASNJA, PREDRAG · 2019 to 2022
$995k
NCATS NIH HHS UL1 TR001442NCI NIH HHS R01 CA244777NCI NIH HHS U01 CA229445NLM NIH HHS R01 LM013107
6 · The paper itself

Abstract

Digital therapeutics (DTx) are a promising way to provide safe, effective, accessible, sustainable, scalable, and equitable approaches to advance individual and population health. However, developing and deploying DTx is inherently complex in that DTx includes multiple interacting components, such as tools to support activities like medication adherence, health behavior goal-setting or self-monitoring, and algorithms that adapt the provision of these according to individual needs that may change over time. While myriad frameworks exist for different phases of DTx development, no single framework exists to guide evidence production for DTx across its full life cycle, from initial DTx development to long-term use. To fill this gap, we propose the DTx real-world evidence (RWE) framework as a pragmatic, iterative, milestone-driven approach for developing DTx. The DTx RWE framework is derived from the 4-phase development model used for behavioral interventions, but it includes key adaptations that are specific to the unique characteristics of DTx. To ensure the highest level of fidelity to the needs of users, the framework also incorporates real-world data (RWD) across the entire life cycle of DTx development and use. The DTx RWE framework is intended for any group interested in developing and deploying DTx in real-world contexts, including those in industry, health care, public health, and academia. Moreover, entities that fund research that supports the development of DTx and agencies that regulate DTx might find the DTx RWE framework useful as they endeavor to improve how DTxcan advance individual and population health.

Indexed as

Behavior TherapyPopulation HealthAlgorithmsHealth BehaviorHumansMedication Adherenceaccessibledecisiondecision-based evidence-makingdecision makingdevelopmentdigital therapeuticsmedication adherencemonitoringpharmaceuticalspublic healthreal-world datareal-world evidencesafetestingtherapeutics

Identifiers

PMID38441954
PMCPMC10951831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.